← Eichor
Study identifier: NCT05177133 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)

Condition: Gastric Adenocarcinoma · Esophageal Adenocarcinoma  ·  Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

PhasePhase 2
Planned participants25
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To investigate the effects of the combination of two chemotherapies followed by immunostimulants on the interferon gamma expression and infiltration of cytotoxic T cells in the tumour microenvironment in patients with previously untreated metastatic or locally advanced esophagogastric cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Joris Bos, MSc  ·  0204440506  ·  j.bos3@amsterdamumc.nl

Always discuss trial participation with your own doctor first.

Locations (8)

Academic Medical Center, Medical OncologyAmsterdam, NetherlandsRecruiting
Amsterdam UMC, location VUmcAmsterdam, NetherlandsRecruiting
Catharina ziekenhuisEindhoven, NetherlandsRecruiting
Medisch Centrum LeeuwardenLeeuwarden, NetherlandsNot Yet Recruiting
LUMCLeiden, NetherlandsNot Yet Recruiting
Radboud UMCNijmegen, NetherlandsRecruiting
Erasmus MCRotterdam, NetherlandsNot Yet Recruiting
UMC UtrechtUtrecht, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05177133